17945-79-8

Basic information

• Product Name: 4-(Pyridin-2-yl)butan-1-ol
• Synonyms: 4-(pyridin-2-yl)butan-1-ol;4-(2-pyridinyl)-1-butanol;2-Pyridinebutanol;4-(2-Pyridyl)-1-butanol
• CAS NO: 17945-79-8
• Molecular Formula: C₉H₁₃NO
• Molecular Weight: 151.21
• Mol File: 17945-79-8.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 269.99 °C at 760 mmHg
• Flash Point: 117.086 °C
• Appearance: /
• Density: 1.036g/cm³
• Vapor Pressure: 0.003mmHg at 25°C
• Refractive Index: 1.524
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: 4-(Pyridin-2-yl)butan-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(Pyridin-2-yl)butan-1-ol(17945-79-8)
• EPA Substance Registry System: 4-(Pyridin-2-yl)butan-1-ol(17945-79-8)

Safety Data

• Hazardous Substances Data: 17945-79-8(Hazardous Substances Data)

Usage

General Description

4-(Pyridin-2-yl)butan-1-ol is a chemical compound with the molecular formula C10H13NO. It belongs to the chemical class known as pyridines and derivatives. Pyridines are compounds containing a pyridine ring, a six-membered aromatic heterocycle, in its structure. The 4-(Pyridin-2-yl)butan-1-ol compound specifically has an alcohol group (-OH) connected to one end of a four-carbon chain (butane), with a pyridine attached to the other end. This chemical is used mainly in the field of organic synthesis, serving as an important raw and intermediate material in the pharmaceutical and agrochemical industries. However, the specific hazard and toxicity characteristics of 4-(pyridin-2-yl)butan-1-ol remain largely unexplored.

InChI:InChI=1/C9H13NO/c11-8-4-2-6-9-5-1-3-7-10-9/h1,3,5,7,11H,2,4,6,8H2

Upstream product

• 84199-93-9 2-(3-ethoxycarbonylpropyl)pyridine 
• 395652-44-5 4-(pyridin-2-yl)but-3-yn-1-ol 
• 84199-92-8 diethyl 2-(2-pyridyl)ethylmalonate 
• 109-04-6 2-bromo-pyridine 
• 58530-53-3 2,4-dibromopyridine 
• 103-74-2 2-(2-Hydroxyethyl)pyridine 
• 121056-68-6 methyl 4-(pyridin-2-yl)butanoate 
• 86480-63-9 methyl(α-methoxycarbonyl)(pyridine)-2-butanoate 
• 16927-00-7 2-(2-chloroethyl)pyridine 
• 100-69-6 2-vinylpyridine 

Downstream Products

• 90943-32-1 4-(2-pyridinyl)butyraldehyde 
• 237763-52-9 1-chloro-4-(2-pyridyl)butane 

Relevant articles and documents

Total Synthesis of Phenanthroquinolizidine Alkaloids Using a Building Block Strategy

A concise and general strategy for the total synthesis of the phenanthroquinolizidine alkaloids has been developed. An iterative Suzuki-Miyaura coupling reaction between the requisite aryl boronic acid, 2-bromo-4,5-dimethoxyphenyl N-methyliminodiacetate (MIDA) boronate derived from boronic acid, and a suitable bromopyridine substrate bearing a homopropargyl alcohol at the 2-position generated the desired ortho-aza-terphenyl compounds. Hydrogenation of the triple bond followed by treatment with methanesulfonyl chloride afforded their corresponding tetrahydroquinolizinium ion intermediates, which were subsequently reacted with NaBH4 to provide the desired hexahydroquinolizine products. A final oxidative electrocyclization reaction gave the target phenanthroquinolizidine natural products. This synthetic approach only requires the use of three chromatographic separations throughout the entire synthesis.

CARBAMATE DERIVATIVES OF LACTAM BASED N-ACYLETHANOLAMINE ACID AMIDASE (NAAA) INHIBITORS

Described herein are compounds and pharmaceutical compositions which inhibit N-acylethanolamine acid amidase (NAAA). Described herein are methods for synthesizing the compounds set forth herein and methods for formulating these compounds as pharmaceutical compositions which include these compounds. Also described herein are methods of inhibiting NAAA in order to sustain the levels of palmitoylethanolamide (PEA) and other N-acylethanolamines (NAE) that are substrates for NAAA, in conditions characterized by reduced concentrations of NAE. Also, described here are methods of treating and ameliorating pain, inflammation, inflammatory diseases, and other disorders in which modulation of fatty acid ethanolamides is clinically or therapeutically relevant or in which decreased levels of NAE are associated with the disorder.

Heterocyclic derivatives of 2-(3,5-dimethylphenyl)tryptamine as GnRH receptor antagonists

A series of heterocyclic 2-(3,5-dimethylphenyl)tryptamine derivatives was prepared and evaluated on a rat gonadotropin releasing hormone receptor assay. The carbon tether length and heterocyclic ring attached to the amino group of 2-(3,5-dimethylphenyl)tr